CD38 and Miyoshi myopathy: It induces anti-MM effect via binding to transmembrane extracellular enzyme CD38 on the membrane of MM plasma cells to induce MM cell lysis.7 In our practice, patients with RRMM were treated by Daratumumab combined with chemotherapy, with the achievement of certain clinical efficacy.